eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin
Zotatifin continues to show favorable activity profile, including two confirmed partial responses (PR) among seven heavily pretreated...
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin
DNA Writing Goes Enzymatic, Encourages Pursuit of Bold Visions
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
Federation Bio Administers First Dose in Phase 1 Clinical Trial
Escient Pharmaceuticals Announces $120 Million Series C Financing
Indigo Expands 2023 Biological Crop Protection Line with New Biofungicide
Neumora Therapeutics Announces $112 Million Series B Financing
eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE